Fate Therapeutics' Series C Round

Fate Therapeutics raised a round of funding on May 09, 2011. Investors include Takeda Ventures.

Fate Therapeutics (NASDAQ: FATE) is a biotechnology company developing stem cell modulators (SCMs), biologic or small molecule compounds that guide cell fate, to treat patients with very few therapeut…

Articles about Fate Therapeutics' Series C Round: